The Infinium Methylation Assay provides quantitative array-based methylation measurement at the single-CpG-site level, offering high resolution for understanding epigenetic changes.
Genome-wide methylation analysis capabilities make this assay highly suitable for studying the biological role of DNA methylation in normal and diseased cells.
The Infinium Methylation Assay detects cytosine methylation at CpG islands based on highly multiplexed genotyping of bisulfite-converted genomic DNA. Upon treatment with bisulfite, unmethylated cytosine bases are converted to uracil, while methylated cytosine bases remain unchanged.
The assay interrogates these chemically differentiated loci using two site-specific probes, one designed for the methylated locus (M bead type), and another for the unmethylated locus (U bead type).
Single-base extension of the probes incorporates a labeled ddNTP, which is subsequently stained with a fluorescent reagent. The level of methylation for the interrogated locus can be determined by calculating the ratio of the fluorescent signals from the methylated vs. unmethylated sites.
The Infinium Methylation Assay is compatible with the iScan microarray imaging system.Learn More About DNA Methylation Analysis
Dr. Partha Majumder uses Infinium MethylationEPIC arrays to look at epigenetic changes in oral cancer cases associated with chewing tobacco.Read Interview
The GLOBAL study integrates imaging, multiomic technologies, and big data, uncovering novel diagnostic and therapeutic targets for common chronic diseases.Read Interview
Learn why Se Hoon Kim, MD, PhD believes that comprehensive genetic profiling of brain tumors would benefit from methylation array analysis.Read Interview
MethylationEPIC BeadChip Kits offer a unique combination of comprehensive, expert-selected coverage, including 99% of RefSeq genes, 95% of CpG islands, ENCODE enhancer regions, and other content categories selected by methylation experts. These features make these kits an ideal solution for epigenome-wide association studies (EWAS).